Heat Biologics (HTBX) Shares are Up 7.41%

Heat Biologics (HTBX) has been under a strong bear grip, hence the stock is down -2.22% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 6.75% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.41% in the last 1 week, and is up 4.38% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Heat Biologics (NASDAQ:HTBX): The stock opened at $0.73 on Friday but the bulls could not build on the opening and the stock topped out at $0.84 for the day. The stock traded down to $0.72 during the day, due to lack of any buying support eventually closed down at $0.74 with a loss of -14.72% for the day. The stock had closed at $0.87 on the previous day. The total traded volume was 1,702,474 shares.


The stock has recorded a 20-day Moving Average of 2.57% and the 50-Day Moving Average is 15.69%. Heat Biologics, Inc. is up 8.99% in the last 3-month period. Year-to-Date the stock performance stands at -69.63%.

Heat Biologics, Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates, which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer, respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live, genetically-modified, irradiated human cells, which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens, thus harnessing a patients own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *